PD-L1-IN-4 

PD-L1-IN-4 (Compound X18) is an orally active PD-L1 inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer^[1].

PD-L1-IN-4 (0.1-10 μM, 24 h) alleviates the immunosuppressive effect of PD-L1 and reduces cell-surface accessible PD-L1 in PD-L1/aAPC/CHO-K1 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pharmacokinetic Analysis in SD Rat Model^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

735.20

C₃₈H₄₀ClFN₄O₈

2597056-86-3

FC1=C(C=CC=C1C2=CC(OCCCN3CCC(CC3)O)=CC=C2)COC4=CC(OCC5=CC6=NON=C6C=C5)=C(C=C4Cl)CN[C@@H](C(O)=O)CO

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liu L, et al. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity. J Med Chem. 2024 Mar 11.  [Content Brief]